Caribou Biosciences, Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Caribou Biosciences, Inc. (CRBU) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $10.40 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-03-05
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $10.40M.
- 2025-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $14.90M.
- 2025-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $21.10M.
- 2024-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $20.90M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2025-12-31 | $10.40M 10-K · filed 2026-03-05 |
| 2025-06-30 | $14.90M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $21.10M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $20.90M 10-K · filed 2025-03-10 |
| 2024-09-30 | $24.50M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $31.10M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $35.00M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $25.80M 10-K · filed 2024-03-11 |
| 2023-09-30 | $29.70M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $31.70M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $34.20M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $26.50M 10-K · filed 2023-03-09 |
| 2022-09-30 | $29.20M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $31.50M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $32.00M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $34.50M 10-K · filed 2022-03-21 |
| 2021-09-30 | $7.70M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |